Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease.
EMPA-KIDNEY Collaborative Group None. et al, (2025), N Engl J Med, 392, 777 - 787
Design, recruitment and baseline characteristics of the LENS trial.
LENS Collaborative Group None., (2024), Diabet Med, 41
ASCEND-Eye: Effects of Aspirin on Diabetic Retinopathy.
Sammons EL. et al, (2024), Ophthalmology, 131, 771 - 779
ASCEND-Eye: Effects of Omega-3 Fatty Acids on Diabetic Retinopathy.
Sammons EL. et al, (2024), Ophthalmology, 131, 526 - 533
Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group None., (2024), Lancet Child Adolesc Health, 8, 190 - 200
Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial.
EMPA-KIDNEY Collaborative Group None., (2024), Lancet Diabetes Endocrinol, 12, 39 - 50
Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial.
EMPA-KIDNEY Collaborative Group None., (2024), Lancet Diabetes Endocrinol, 12, 51 - 60
ASCEND-Eye: Rationale, design and baseline characteristics for a sub-study of the ASCEND randomised trial, exploring the effects of aspirin and omega-3 fatty acids on diabetic retinopathy and age-related macular degeneration.
Sammons E. et al, (2023), Contemp Clin Trials Commun, 35
Reliability of major bleeding events in UK routine data versus clinical trial adjudicated follow-up data.
Harper C. et al, (2023), Heart, 109, 1467 - 1472
Empagliflozin in Patients with Chronic Kidney Disease.
The EMPA-KIDNEY Collaborative Group None. et al, (2023), N Engl J Med, 388, 117 - 127
Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis.
RECOVERY Collaborative Group None., (2022), Lancet, 400, 359 - 368
Harmonisation of large-scale, heterogeneous individual participant adverse event data from randomised trials of statin therapy.
Cholesterol Treatment Trialists' Collaboration None., (2022), Clin Trials
Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial.
EMPA-KIDNEY Collaborative Group None., (2022), Nephrol Dial Transplant, 37, 1317 - 1329
Effects of aspirin on dementia and cognitive function in diabetic patients: the ASCEND trial.
Parish S. et al, (2022), Eur Heart J, 43, 2010 - 2019
Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease.
HPS3/TIMI55-REVEAL Collaborative Group None. et al, (2022), Eur Heart J, 43, 1416 - 1424
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group None., (2022), Lancet, 399, 665 - 676
Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group None., (2022), Lancet, 399, 143 - 151